Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Oncotarget 8: 86798692
Regulatory bodies including the MHRA and European Medicines Agency (EMA) continue to monitor safety data, and current product information for GLP-1 agonists includes cholelithiasis and cholecystitis as recognised adverse reactions
Diabetes Care 35:12251231 Russell-Jones D, Cuddihy RM, Hanefeld M et al (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
Food and Drug Administration has recently identified drug-induced alopecia (hair loss) as an adverse event for patients taking GLP-1 medications
It makes sleep apnea symptoms worse
